The framework of the LIFE study allowed us to overcome these limitations and demonstrates that the altered ratios are useful not only for prognostic classification of HNSCC-CPs but also as a biomarker for bias-free detection of HNSCC-CPs. This evidence concerns the gene CAD and head and neck squamous cell carcinoma.